SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kilitch Drugs (India) informs about board meeting

28 Aug 2018 Evaluate

Kilitch Drugs (India) has informed that the meeting of the Board of Directors of the Company is scheduled on 31/08/2018, to consider and approve the conversion of 16,00,000 Warrants issued at a price of Rs 59 per warrant and allotment of 16,00,000 Equity shares of face value of Rs 10 each pursuant to such conversion of Warrants. Further, pursuant to applicable provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company shall remain closed from August 28, 2018 to August 31, 2018 for the Directors, Officers and all the designated Employees of the Company for prevention of insider trading.

The above information is a part of company’s filings submitted to BSE.

Kilitch Drugs(India) Share Price

135.10 4.55 (3.49%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×